| Literature DB >> 23645717 |
Elizabeth Heinrichs-Graham1, Tony W Wilson2, Pamela M Santamaria3, Sheila K Heithoff4, Diego Torres-Russotto4, Jessica A L Hutter-Saunders5, Katherine A Estes5, Jane L Meza6, R L Mosley5, Howard E Gendelman5.
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder associated with debilitating motor, posture, and gait abnormalities. Human studies recording local field potentials within the subthalamic nucleus and scalp-based electroencephalography have shown pathological beta synchronization throughout the cortical-basal ganglia motor network in PD. Suppression of such pathological beta synchronization has been associated with improved motor function, which may explain the effectiveness of deep-brain stimulation. We used magnetoencephalography (MEG) to investigate neural population-level beta responses, and other oscillatory activity, during a motor task in unmedicated patients with PD and a matched group of healthy adults. MEG is a noninvasive neurophysiological technique that permits the recording of oscillatory activity during movement planning, execution, and termination phases. Each of these phases was independently examined using beamforming to distinguish the brain areas and movement phases, where pathological oscillations exist during motor control. Patients with PD exhibited significantly diminished beta desynchronization compared with controls prior to and during movement, which paralleled reduced alpha desynchronization. This study is the first to systematically investigate neural oscillatory responses in PD during distinct stages of motor control (e.g. planning, execution, and termination) and indicates that these patients have significant difficulty suppressing cortical beta synchronization during movement planning, which may contribute to their diminished movement capacities.Entities:
Keywords: MEG; cortex; magnetoencephalography; motor control; oscillations
Mesh:
Year: 2013 PMID: 23645717 PMCID: PMC4153806 DOI: 10.1093/cercor/bht121
Source DB: PubMed Journal: Cereb Cortex ISSN: 1047-3211 Impact factor: 5.357
Clinical and demographic characteristics
| Subject ID | Age (years) | Sex | Disease duration (years) | PD medications (type, dose) | UPDRS off | UPDRS on |
|---|---|---|---|---|---|---|
| p01a | 75 | M | 4 | Pram (0.5 mg), CD/LD (25/100 mg) | – | 17 |
| p02 | 57 | M | 2.5 | Pram (3 mg) | 47 | 36 |
| p03 | 62 | M | 4 | Pram (4.5 mg), Rasagiline (1 mg) | 32 | 31 |
| p04 | 70 | M | – | Pram (1.5 mg), CD/LD (25/100 mg) | 30 | – |
| p05 | 52 | M | 9 | CD/LD, Ropinirole | 80 | 60 |
| p06a | 70 | M | 5.5 | Rasagiline, Pram | 37 | 32 |
| p07a | 76 | M | 4 | Rasagiline (1 mg), CD/LD (50/200 mg) | 64 | 55 |
| p08 | 61 | M | – | Ropinirole (1 mg) | 23 | – |
| p09 | 60 | M | 1 | Ropinirole (1 mg) | 51 | 48 |
| p10 | 72 | F | 9 | Ropinirole | 17 | 17 |
| p11a | 77 | M | 6 | CD/LD | – | – |
| p12a | 54 | F | 6 | Pram (4.5 mg), CD/LD (25/100 mg) | 48 | 37 |
| p13 | 64 | F | 8 | Pram (2 mg), Rasagiline (1 mg) | 49 | 41 |
| p14 | 67 | M | 1 | CD/LD (25/100 mg) | 34 | 31 |
| p15 | 66 | M | 3 | Rasagiline (1 mg), CD/LD (25/100 mg) | 73 | 73 |
| p16 | 69 | M | – | CD/LD (50/200 mg) | 52 | 43 |
| p17 | 52 | M | 6 | Ropinirole (8mg) | 24 | 23 |
| p18a | 60 | M | 3 | CD/LD (25/100 mg), Aman (100 mg) | 49 | 40 |
| p19 | 64 | M | 7 | CD/LD (25/100 mg), Aman | 36 | 27 |
| c01 | 68 | F | ||||
| c02a | 60 | F | ||||
| c03 | 69 | F | ||||
| c04 | 56 | M | ||||
| c05 | 69 | M | ||||
| c06 | 56 | M | ||||
| c07a | 70 | M | ||||
| c08 | 64 | M | ||||
| c09 | 83 | F | ||||
| c10 | 85 | M | ||||
| c11 | 53 | F | ||||
| c12 | 75 | M | ||||
| c13 | 71 | M | ||||
| c14 | 68 | M | ||||
| c15 | 53 | M | ||||
| c16a | 50 | M |
Pram: pramipexole; CD/LD: carbidopa/levodopa; Aman: amantadine.
aDenotes participants who were excluded from analysis due to major dental artifacts, large or repetitive head movements, or tremor-related (or exasperated) artifacts.
Figure 1.Motor paradigm. Participants fixated on the cross hair as the red dot moved clockwise toward the blue dots, displacing each green dot in turn. Participants were instructed to make one flexion-extension movement each time the red dot was within the blue area, but only one movement per revolution (figure and caption adapted from Wilson et al. 2010).
Figure 2.Single-trial accelerometer signals from a representative control and patient with PD. Time in ms is denoted on the x-axis, while acceleration in arbitrary units (a.u.) is noted on the y-axis. All patients and controls exhibited a sharp change in signal amplitude at movement onset; this change was marked as 0 ms in each trial. This sharp change in accelerometer signal amplitude allowed precise definitions of movement onset during individual trials, regardless of participant group.
Figure 3.Average time–frequency spectra in controls and patients with PD during movement. Time (in ms) is denoted on the x-axis, with 0 ms defined as movement onset. Frequency (in Hz) is shown on the y-axis. The average patterns of alpha and beta premovement desynchronization and PMBR during the hand movement task, expressed as percent difference from baseline, are shown in the control group on the left. The reduced alpha and beta desynchronizations, as well as a diminished beta rebound in the same region, can be discerned in the PD group average on the right. In addition, the lower-frequency gamma response that occurred at movement onset can be seen in the average plot of the patients with PD. This gamma response was present in a subset of patients and controls (see Supplementary Data).
Figure 4.Activation differences during the premovement beta ERD and the alpha ERD. The peak difference in the beta ERD response (top panel) was within the left motor hand knob feature of the precentral gyrus and extended onto the adjacent postcentral gyrus (P = 0.035, corrected). Differences seen in the right precentral gyrus near the hand knob region were not significant after permutation testing (P < 0.005, uncorrected and P = 0.107, corrected). The peak difference in the alpha ERD response corresponded to the left postcentral gyrus near the hand knob region (P < 0.05, corrected). All images have been thresholded at P = 0.001, uncorrected, and reflect areas of greater activation in controls compared with patients with PD.
Motor task and group effects: peak coordinates
| Effect | Frequency band | Anatomical label | Talaraich coordinates ( | |||
|---|---|---|---|---|---|---|
| Task effects: controls | Beta ERD | L precentral gyrus | −32 | −21 | 40 | 11.53 |
| R precentral gyrus | 48 | −24 | 40 | 13.93 | ||
| Alpha ERD | L postcentral gyrus | −40 | −32 | 52 | 9.533 | |
| R postcentral gyrus | 47 | −22 | 38 | 8.411 | ||
| PMBR | L premotor cortex | −40 | 10 | 41 | 7.436 | |
| R premotor cortex | 36 | 2 | 40 | 8.647 | ||
| SMA | 10 | −3 | 40 | 8.103 | ||
| Task effects: patients | Beta ERD | L precentral gyrus | −35 | −27 | 30 | 10.09 |
| R precentral gyrus | 41 | −28 | 34 | 6.154 | ||
| Alpha ERD | PCC | 8 | −49 | 21 | 11.53 | |
| PMBR | MPFC | −4 | 34 | 37 | 5.821a | |
| Group effects: controls > patients | Beta ERD | L precentral gyrus | −31 | −30 | 59 | 4.098 |
| L postcentral gyrus | −35 | −32 | 52 | 4.462 | ||
| R precentral gyrus | 45 | −18 | 52 | 4.057b | ||
| Alpha ERD | L postcentral gyrus | −38 | −35 | 61 | 5.229 | |
| R postcentral gyrus | 43 | −16 | 47 | 3.832b | ||
| PMBR | L DLPFC | −44 | 36 | 4 | 3.684b | |
| SMA | 18 | 11 | 40 | 2.861b | ||
Peaks for all task effects were significant at P < 0.0001, corrected, unless noted otherwise.
Peaks for all group effects were significant at P < 0.05, corrected, unless noted otherwise.
aDenotes peaks that were significant at P < 0.01, corrected.
bDenotes peaks that were significant at P < 0.005, uncorrected.